Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CKS1B | P61024 | 4/20 | 0.41 |
| ▸ | SKP1 | P63208 | 4/20 | 0.41 |
| ▸ | SKP2 | Q13309 | 4/20 | 0.41 |
| ▸ | SCD | O00767 | 2/20 | 0.38 |
| ▸ | MCHR1 | Q99705 | 5/20 | 0.36 |
| ▸ | HTR2A | P28223 | 1/20 | 0.35 |
| ▸ | DRD3 | P35462 | 1/20 | 0.35 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.35 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.35 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.34 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.34 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.34 |
| ▸ | HDAC10 | Q969S8 | 1/20 | 0.34 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.34 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.34 |
| ▸ | SMO | Q99835 | 1/20 | 0.33 |
| ▸ | PDPK1 | O15530 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL345775 | 0.90 | CKS1B (0.39) | CKS1BSKP1SKP2SCDMCHR1 | |
| SCHEMBL346479 | 0.86 | TSHR (0.42) | MCHR1CHRM4HRH3 | |
| SCHEMBL345182 | 0.76 | CHRM4 (0.45) | CHRM2CHRM4HDAC6 | |
| SCHEMBL2328595 | 0.72 | CHRM4 (0.51) | CKS1BSKP1SKP2SCDCHRM2 | |
| SCHEMBL9993531 | 0.72 | DGAT1 (0.34) | SCDMCHR1 | |
| SCHEMBL8513298 | 0.71 | CHRM4 (0.34) | HDAC3HDAC2CHRM4HDAC10HDAC6 | |
| SCHEMBL8513303 | 0.71 | CHRM4 (0.34) | HDAC3HDAC2CHRM4HDAC10HDAC6 | |
| SCHEMBL345341 | 0.71 | CHRM4 (0.42) | CKS1BSKP1SKP2SCDCHRM4 | |
| SCHEMBL9994152 | 0.71 | DGAT1 (0.37) | SCDMCHR1HDAC3HDAC2 | |
| SCHEMBL8510771 | 0.70 | SCD (0.35) | SCDMCHR1HDAC3HDAC2HDAC6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120015950-A1 | CARBAMATE DERIVATIVES OF ALKYL-HETEROCYCLES, PREPARATION THEREOF AND THERAPEUTIC USE THEREOF | SANOFI-AVENTIS (FR) | 2012-01-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120015950-A1 | CARBAMATE DERIVATIVES OF ALKYL-HETEROCYCLES, PREPARATION THEREOF AND THERAPEUTIC USE THEREOF | INTS9, CDK8, SCN8A | CKS1B 1161/4885SKP1 4281/4885SKP2 3646/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.